Möchten Sie immer auf dem neuesten Stand bleiben?

Bemærk venligst, at rapporten udelukkende forefindes på engelsk ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK’s revenue grew by...

ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK’s revenue grew by 11% in Q2 2023, driven by 17% growth in tablet sales and...

ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for første halvår (Q2) 2023 torsdag den 24. august 2023. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for investorer og...

On Thursday, 24 August 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its six-month interim report (Q2) 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm...

ALK (ALKB:DC / OMX: ALK B / AKBLF) meddeler i dag, at Carsten Hellmann fratræder som administrerende direktør ved udgangen af 2023. Han efterfølges af Peter Halling senest den 1. januar 2024. ...

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that Carsten Hellman will step down as President & CEO at the end of 2023. He will be succeed by Peter Halling no later than 1 January 2024. The...

Studiet mødte sit primære og alle væsentlige sekundære endemål med en forbedring i den totale kombinerede allergiske rhinitis-score (TCRS) på 22 % sammenlignet med placebo (primært endemål)....

Primary and all key secondary confirmatory endpoints were met, with an improvement in the total combined allergic rhinitis score (TCRS) of 22% compared to placebo (primary endpoint). Results were...

Bemærk venligst, at rapporten udelukkende forefindes på engelsk. Revenue up 7%, full-year outlook maintained (unaudited) ALK’s overall results in Q1 2023 were largely as expected, with 7% organic...

Revenue up 7%, full-year outlook maintained (unaudited) ALK’s overall results in Q1 2023 were largely as expected, with 7% organic revenue growth in local currencies and increased operating profit...